Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient-Focused Drug Development At 10: Where Does It Go From Here?

Executive Summary

FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?

You may also be interested in...



FDA Considers Incorporating Patient Input In Generic Drug Assessments

The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.

US FDA Considers Incorporating Patient Input In Generic Drug Assessments

But the popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.

Patient Advocates Continue To Push US FDA For Central Office

Will a meeting with the agency's new principal deputy commissioner help assure creation of new access point for patient engagement?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel